Innovent Biologics’ Post

Uncover the power of the Diet Induced Obese (DIO) B6 mouse for drug discovery. In this upcoming webinar, Dr. Ditte Olsen will discuss the versatility of this mouse model, from obesity and type 2 diabetes studies to compound screening and mechanistic research. Register today to get insight into the differences between available DIO models related to substrain and other factors: https://bit.ly/3rc63bj Don't miss out on the chance to ask an expert questions about your study design and model selection after the live presentation! #NASH #metabolicdisease

Are you attending the American Diabetes Association’s 84th Scientific Sessions? Don’t miss our interactive symposium, "Striking a Balance: The Role of Glucagon Agonism to Improve Obesity and Metabolic Care." 📅 Date: Sunday, June 23, 2024 ⏰ Time: 7:00 PM - 8:30 PM ET Learn from two renowned obesity experts as they share cutting-edge insights and practice-changing data on novel therapeutic targets like glucagon agonism. This is a unique opportunity to enhance your clinical practice with the latest advancements in obesity treatment. https://bit.ly/4bq5Ovk

GLP-1 receptor agonists, once used exclusively for diabetes treatment, are emerging as a new category of #weightlossmedications with big potential in #obesitymanagement. Their popularity has significantly risen since 2021 when they were first approved for extended weight management. Raul J. Rosenthal, MD, FASMBS, explains how these latest advancements are transforming obesity care: https://cle.clinic/4exgeuW

Hoping to see some familiar (and new) faces at the upcoming @AAPSComms PharmSci 360 meeting (#PharmSci360). Join me at my session [Clinical Bioanalysis of Maridebart Cafraglutide (Formerly AMG 133), a Bispecific Molecule for Obesity]: https://lnkd.in/gUpNKbuT

Exciting News in Obesity Treatment! Prof Jerry Greenfield of St Vincent’s Clinic and the Garvan Institute of Medical Research discusses new medications targeting GLP-1 and GIP receptors which offer hope for effective obesity management. They reduce appetite, help with weight loss, and assist insulin release for type 2 diabetes patients. Some side effects, like nausea, are manageable. However, a shortage of semaglutide (Ozempic) is expected in 2023-2024, highlighting growing demand. The newly approved tirzepatide (Mounjaro) can help shed 15-20 kilograms. While these treatments show promise, caution is needed for individuals with specific medical histories and potential stomach issues before certain procedures. Excitingly, the future holds the potential for "Triple G" receptor agonists, offering even more effective weight loss solutions. Read more: https://lnkd.in/gZDe7ZAS St Vincent's Clinic Research Foundation. #ObesityTreatment #HealthcareInnovation #StVincentsClinic #Endocrinology #DiabetesManagement

Exciting News! Boehringer Ingelheim is forging ahead with survodutide (BI 456906) in three Phase 3 studies for individuals battling overweight or obesity. In a Phase 2 study, after 46 weeks of treatment, survodutide showcased an impressive 19% weight reduction. 𝙒𝙚'𝙧𝙚 𝙘𝙤𝙢𝙢𝙞𝙩𝙩𝙚𝙙 𝙩𝙤 𝙖𝙙𝙙𝙧𝙚𝙨𝙨𝙞𝙣𝙜 𝙩𝙝𝙚 𝙪𝙣𝙢𝙚𝙩 𝙣𝙚𝙚𝙙 𝙛𝙤𝙧 𝙚𝙛𝙛𝙚𝙘𝙩𝙞𝙫𝙚 𝙤𝙗𝙚𝙨𝙞𝙩𝙮 𝙩𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨. Stay tuned for updates! 💪💊 read more on this: https://lnkd.in/e6f4VD3g 👉 be sure to follow the Practical Patient Care page and don't forget to sign up to receive our weekly newsletter #diagnostics #woundcare #infectionprevention #criticalcare #followus #BoehringerIngelheim #ObesityResearch #PharmaceuticalInnovation #ClinicalTrials #HealthcareSolutions

Addressing obesity as a chronic condition, the SURMOUNT-4 trial explored the efficacy of tirzepatide, a medication combining GIP and GLP-1 receptor agonism, in maintaining weight loss. The trial involved a 36-week open-label tirzepatide lead-in treatment period followed by a 52-week double-blind, placebo-controlled phase. The study revealed significant weight maintenance and additional reduction in participants continuing tirzepatide compared to those switched to placebo. Tirzepatide demonstrated consistent improvements in cardiometabolic parameters and patient-reported outcomes, with an acceptable safety profile.

📣Meet Sapna Sharma, Group leader at TUM in Munich, Germany, in the latest episode of 🎧TheMetabolomist. She and Alice Limonciel discuss the role of metabolomics in multi-omics studies, maximizing the use of available omic data, and transitioning from mere associations to causal relationships and their medical implications, especially concerning Type 2 diabetes. Listen now: https://lnkd.in/dDyXWtpu #Metabolomics, #Diabetes, #Loveyourmetabolites, #Research

In obesity clinical trials, the typically used weight loss endpoints in kg or % of body weight give limited insights regarding drug efficacy and body composition changes. Integrating MRI-based measures of body and muscle composition will give more information about the source of the weight loss and other effects of the drug. Read more here: https://lnkd.in/dhayBgZw #clinicaltrials #obesity #weightloss

🔊 Latest news!   🔬 Mesothelial cells in omental adipose tissue hinder adipogenesis The discovery, made by EPFL, that omental fat has a mechanism to limit adipocyte formation may lead to new treatments for obesity and metabolic disease. Click on the link in the comments to read more 👇 #obesity #mesothelial #adipogenesis